Junpei Yamaguchi

Dr. Junpei Yamaguchi


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Annals of Surgery
Verified
Journal Article
Closed access
JYJunpei Yamaguchi
Junpei Yamaguchi
YYYukihiro Yokoyama
Yukihiro Yokoyama
TFTsutomu Fujii
Tsutomu Fujii
SYSuguru Yamada
Suguru Yamada
HTHideki Takami
Hideki Takami
TETomoki Ebata
Tomoki Ebata
Objective: Given the frequent adverse events with multidrug chemotherapy, not only the survival benefit but also the feasibility of using neoadjuvant chemotherapy to treat pancreatic cancer need to be clarified. Summary of Background Data: Although the development of multidrug chemotherapy regimens has improved the survival outcomes of patients with unresectable pancreatic cancer, the benefits of these treatments in the neo-adjuvant setting remain controversial. Methods: Patients with borderline-resectable pancreatic cancer were enrolled and randomly assigned to receive neoadjuvant chemotherapy with either FOLFIRINOX or gemcitabine with nab-paclitaxel (GEM/nab-PTX). After the completion of chemotherapy, patients underwent surgical resection when feasible. This study (NUPAT-01) was a randomized phase II trial, and the primary endpoint was the R0 resection rate. Results: Fifty-one patients were enrolled in this study [FOLFIRINOX (n = 26) and GEM/nab-PTX (n = 25)]. A total of 84.3% (n = 43/51) of the patients eventually underwent surgery, and R0 resection was achieved in 67.4% (n = 33/ 51) of the patients. Adverse events (grade >3) due to neoadjuvant treatment were observed in 45.1% of the patients (n = 23/51), and major surgical complications occurred in 30.0% (n = 13/43), with no mortality noted. The intention-to-treat analysis showed that the 3-year overall survival rate was 54.7%, with a median survival time of 39.4 months, and a significant difference in overall survival was not observed between the FOLFIRINOX and GEM/nab-PTX groups. Conclusions: These results indicate that neoadjuvant chemotherapy with FOLFIRINOX or GEM/nab-PTX is feasible and well tolerated, achieving an R0 resection rate of 67.4%. The survival of patients was even found to be favorable in the intention-to-treat analysis.

4 March 2017 in Surgery Today
Verified
Journal Article
Closed access
PDF file
JYJunpei Yamaguchi
Junpei Yamaguchi
YYYukihiro Yokoyama
Yukihiro Yokoyama
TKToshio Kokuryo
Toshio Kokuryo
TETomoki Ebata
Tomoki Ebata
MNMasato Nagino
Masato Nagino

23 July 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JYJunpei Yamaguchi
Junpei Yamaguchi
YYYukihiro Yokoyama
Yukihiro Yokoyama
TKToshio Kokuryo
Toshio Kokuryo
TETomoki Ebata
Tomoki Ebata
Atsushi EnomotoAtsushi Enomoto
Atsushi Enomoto
MNMasato Nagino
Masato Nagino
The tumor-suppressive role of trefoil factor family (TFF) members in gastric carcinogenesis has been suggested, but their significance and mechanisms in other digestive diseases remain elusive. To clarify the role of TFF1 in pancreatic carcinogenesis, we performed IHC on human samples, transfected siRNA against TFF1 into pancreatic cancer cell lines, and employed mouse models in which PanIN development and loss of TFF1 occur simultaneously. In human samples, the expression of TFF1 was specifically observed in pancreatic intraepithelial neoplasm (PanIN), but was frequently lost in the invasive component of pancreatic ductal adenocarcinoma (PDAC). When the expression of TFF1 was suppressed in vitro, pancreatic cancer cell lines showed enhanced invasive ability and features of epithelial-mesenchymal transition (EMT), including upregulated Snail expression. TFF1 expression was also observed in PanIN lesions of Pdx-1 Cre; LSL-KRASG12D (KC) mice, a model of pancreatic cancer, and loss of TFF1 in these mice resulted in the expansion of PanIN lesions, an EMT phenotype in PanIN cells, and an accumulation of cancer-associated fibroblasts (CAFs), eventually resulting in the development of invasive adenocarcinoma. This study indicates that the acquisition of TFF1 expression is an early event in pancreatic carcinogenesis and that TFF1 might act as a tumor suppressor to prevent EMT and the invasive transformation of PanIN.

16 November 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
YOYosuke Ochiai
Yosuke Ochiai
JYJunpei Yamaguchi
Junpei Yamaguchi
TKToshio Kokuryo
Toshio Kokuryo
YYYukihiro Yokoyama
Yukihiro Yokoyama
TETomoki Ebata
Tomoki Ebata
MNMasato Nagino
Masato Nagino

1 November 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YHYuki Hayashi
Yuki Hayashi
JYJunpei Yamaguchi
Junpei Yamaguchi
TKToshio Kokuryo
Toshio Kokuryo
TETomoki Ebata
Tomoki Ebata
YYYukihiro Yokoyama
Yukihiro Yokoyama
MNMasato Nagino
Masato Nagino

27 August 2015 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
TTT. Takagi
T. Takagi
YYYukihiro Yokoyama
Yukihiro Yokoyama
TKT. Kokuryo
T. Kokuryo
JYJunpei Yamaguchi
Junpei Yamaguchi
MNM. Nagino
M. Nagino